A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer

Nuclear Medicine and Biology

Volumn 33, Issue 6, 2006, Pages 715-722

  El Mabhouh, Amal A ^a   Angelov, Christo A ^a   Cavell, Ron ^a   Mercer, John R ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

99mTc labeling; Bisphosphonates; Gemcitabine; Metastatic bone disease; Targeted chemotherapy

Indexed keywords

GEMCITABINE BISPHOSPHONATE TC 99M; HYDROXYAPATITE; MEDRONATE TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BISPHOSPHONIC ACID DERIVATIVE; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GEMCITABINE; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COW; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TARGETING; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; URINARY EXCRETION; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; KIDNEY; LIVER; METABOLISM; METASTASIS; TISSUE DISTRIBUTION;

ANIMALS; BONE NEOPLASMS; DEOXYCYTIDINE; DIPHOSPHONATES; FEMALE; KIDNEY; LIVER; MICE; MICE, INBRED BALB C; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 33747363746     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.06.004     Document Type: Article

References (26)

1. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2005, Toronto, Canada, 2005. http://www.cancer.ca/vgn/images/portal/cit_86751114/48/28/401594768cw_2005stats_en.pdf.
2. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5 (2001), IARC Press, Lyon
3. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 (2001) 165-176
4. Lake D.E., and Hudis C.A. High-dose chemotherapy in breast cancer. Drugs 64 (2004) 1851-1860
5. Fleisch H. Bisphosphonates: mechanisms of action. Endocrinol Rev 19 (1998) 80-100
6. Uludag H., and Yang J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol Prog 18 (2002) 604-611
7. El-Mabhouh A., Angelov C., McEwan A., Jia G., and Mercer J. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer. Cancer Biotherap Radiopharm 19 (2004) 627-640
8. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases. Appl Radiat Isot 62 (2005) 541-549
9. Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs 22 (1999) 176-183
10. Kantoci D., Denike J.K., and Wechter W.J. Synthesis of aminobisphosphonates. Synth Comm 26 (1996) 2037-2042
11. Veerman G., Ruiz van Haperen V.W., Vermorken J.B., Noordhuis P., Braakhuis B.J., Pinedo H.M., et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 38 (1996) 335-342
12. Boven E., Schipper H., Erkelens C.A.M., Hatty S.A., and Pinedo H.M. The influence of the schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. Br J Cancer 68 (1993) 52-56
13. Braakhuis B.J.M., Ruiz van Haperen V.W.T., Boven E., Veerman G., and Peters G.J. Schedule dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 22 Suppl 11 (1995) 42-46
14. Schultz R.M., Merriman R.L., Toth J.E., Zimmermann J.E., Hertel L.W., Andis S.L., et al. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5 (1993) 223-228
15. Hays M.T., and Berman M. Pertechnetate distribution in man after intravenous infusion: a compartmental model. J Nucl Med 18 (1977) 898-904
16. Hosain F., Spencer R.P., Couthon H.M., and Sturtz G.L. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med 37 (1996) 105-107
17. Arteaga-de-Murphy C., Melendez-Alafort L., Montoya-Molina C.E., and Sepulveda-Mendez J. Radiopharmacokinetic data for 99mTc-ABP: a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP. Nucl Med Biol 24 (1997) 27-33
18. Laznicek M., Laznickova A., and Budsky F. 99Tcm-DTPMP as a skeletal scintigraphy agent: distribution in rats in comparison with 99Tcm-MDP. Nucl Med Commun 17 (1996) 1016-1020
19. Kanishi D. 99mTc-MDP accumulation mechanisms in bone. Oral Surg Oral Med Oral Pathol 75 (1993) 239-246
20. Okamoto Y. Accumulation of technetium-99m methylene diphosphonate: conditions affecting absorption to hydroxyapatite. Oral Surg Oral Med Oral Pathol 80 (1995) 115-119
21. Szeto C.C., and Chow K.M. Nephrotoxicity related to new therapeutic compounds. Ren Fail 27 (2005) 329-333
22. Hirschberg R. Nephrotoxicity of third-generation intravenous bisphosphonates. Toxicology 196 (2004) 165-167
23. Barri Y.M., Munshi N.C., Sukumalchantra S., Abulezz S.R., Bonsib S.M., Wallach J., et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65 (2004) 634-641
24. Markowitz G.S., Appel G.B., Fine P.L., Funvez A.Z., Loon N.R., Jagannath S., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12 (2001) 1164-1172
25. Shipley L.A., Brown T.J., Cornpropst J.D., Hamilton M., Daniels W.D., and Culp H.W. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20 (1992) 849-855
26. Buesa J.M., Losa R., Fernandez A., Sierra M., Esteban E., Diaz A., et al. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 15 101 (2004) 2261-2269